Login to Your Account



Other News To Note


Tuesday, April 26, 2011
KemPharm Inc., of North Liberty, Iowa, said that its attention deficit hyperactivity disorder candidate, KP106, will be formulated in an oral film dosage form in collaboration with MonoSol Rx LLC, of Warren, N.J.. MonoSol acquired exclusive manufacturing rights for the drug in exchange for a share of royalties. It will be responsible for the costs of developing the formulation and manufacturing the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription